Oncolytics Biotech Inc. (TSE:ONC – Free Report) – Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Oncolytics Biotech in a research note issued to investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.42) per share for the year, down from their previous forecast of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2026 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.26) EPS and FY2029 earnings at $0.00 EPS.
Oncolytics Biotech Trading Down 1.3%
Oncolytics Biotech stock opened at C$14.90 on Friday. The stock has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a fifty-two week low of C$0.44 and a fifty-two week high of C$2.08. The firm’s fifty day moving average price is C$14.90 and its 200-day moving average price is C$14.90. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
See Also
- Five stocks we like better than Oncolytics Biotech
- Coherent Stock Is Cooling Off Just as Its AI Thermal Opportunity Heats Up
- Moderna’s 177% Surge Has Investors Asking What Comes Next
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
